New therapies for atopic dermatitis: How will they impact skin care?

Donald Y.M. Leung; Amy S. Paller; Emma Guttman-Yassky

doi:10.1016/j.anai.2022.01.023

New therapies for atopic dermatitis: How will they impact skin care?

Donald Y.M. Leung, Amy S. Paller, Emma Guttman-Yassky

Dermatology

Research output: Contribution to journal › Editorial › peer-review

5 Scopus citations

Original language	English (US)
Pages (from-to)	344-345
Number of pages	2
Journal	Annals of Allergy, Asthma and Immunology
Volume	128
Issue number	4
DOIs	https://doi.org/10.1016/j.anai.2022.01.023
State	Published - Apr 2022

ASJC Scopus subject areas

Immunology and Allergy
Immunology
Pulmonary and Respiratory Medicine

Access to Document

10.1016/j.anai.2022.01.023

Cite this

@article{87020ab7d07641e099e7c7b741052f71,

title = "New therapies for atopic dermatitis: How will they impact skin care?",

author = "Leung, {Donald Y.M.} and Paller, {Amy S.} and Emma Guttman-Yassky",

note = "Funding Information: Funding: This study is funded by the Edelstein Family Chair of Pediatric Allergy-Immunology. Funding Information: The authors acknowledge Nicole Meiklejohn for her assistance in preparing this manuscript. Disclosures: Dr Leung is an employee at the National Jewish Health and has consulted with Incyte Corporation, Leo Pharma, Sanofi-Genzyme Pharma, and Regeneron Pharmaceuticals. Dr Paller is an employee at Northwestern; reports receiving research funds from AbbVie, Eli Lilly, Incyte, and Regeneron; and has consulted with AbbVie, Almirall, Arcutis, Arena, BiomX, Bristol Myers Squibb, Catawba, Eli Lilly, Gilead, Incyte, Janssen, Leo, Novartis, Pfizer, RAPT, Regeneron, Sanofi/Genzyme, and Seanergy. Dr Guttman-Yassky is an employee of Mount Sinai; reports receiving research funds (grants paid to the institution) from AbbVie, Almirall, Amgen, AnaptysBio, Asana Biosciences, AstraZeneca, Boerhinger-Ingelhiem, Cara Therapeutics, Celgene, Eli Lilly, Galderma, Glenmark/Ichnos Sciences, Innovaderm, Janssen, KAO, Kiniksa, Kyowa Kirin, Leo Pharma, Novan, Novartis, Pfizer, Ralexar, Regeneron Pharmaceuticals, and UCB; and is a consultant for AbbVie, Almirall, Amgen, Arena, Asana Biosciences, Aslan Pharmaceuticals, AstraZeneca, Boerhinger-Ingelhiem, Bristol-Meyers Squibb, Cara Therapeutics, Celgene, Connect Pharma, Eli Lilly, EMD Serono, Evidera, Galderma, Ichnos Sciences, Incyte, Janssen Biotech, Kyowa Kirin, Leo Pharma, Pandion Therapeutics, Pfizer, RAPT Therapeutics, Regeneron Pharmaceuticals, Inc, Sanofi, SATO Pharmaceutical, Siolta Therapeutics, Target Pharma Solutions, UCB, and Ventyx Biosciences. Funding: This study is funded by the Edelstein Family Chair of Pediatric Allergy-Immunology.",

year = "2022",

month = apr,

doi = "10.1016/j.anai.2022.01.023",

language = "English (US)",

volume = "128",

pages = "344--345",

journal = "Annals of Allergy, Asthma and Immunology",

issn = "1081-1206",

publisher = "American College of Allergy, Asthma and Immunology",

number = "4",

}

TY - JOUR

T1 - New therapies for atopic dermatitis

T2 - How will they impact skin care?

AU - Leung, Donald Y.M.

AU - Paller, Amy S.

AU - Guttman-Yassky, Emma

N1 - Funding Information: Funding: This study is funded by the Edelstein Family Chair of Pediatric Allergy-Immunology. Funding Information: The authors acknowledge Nicole Meiklejohn for her assistance in preparing this manuscript. Disclosures: Dr Leung is an employee at the National Jewish Health and has consulted with Incyte Corporation, Leo Pharma, Sanofi-Genzyme Pharma, and Regeneron Pharmaceuticals. Dr Paller is an employee at Northwestern; reports receiving research funds from AbbVie, Eli Lilly, Incyte, and Regeneron; and has consulted with AbbVie, Almirall, Arcutis, Arena, BiomX, Bristol Myers Squibb, Catawba, Eli Lilly, Gilead, Incyte, Janssen, Leo, Novartis, Pfizer, RAPT, Regeneron, Sanofi/Genzyme, and Seanergy. Dr Guttman-Yassky is an employee of Mount Sinai; reports receiving research funds (grants paid to the institution) from AbbVie, Almirall, Amgen, AnaptysBio, Asana Biosciences, AstraZeneca, Boerhinger-Ingelhiem, Cara Therapeutics, Celgene, Eli Lilly, Galderma, Glenmark/Ichnos Sciences, Innovaderm, Janssen, KAO, Kiniksa, Kyowa Kirin, Leo Pharma, Novan, Novartis, Pfizer, Ralexar, Regeneron Pharmaceuticals, and UCB; and is a consultant for AbbVie, Almirall, Amgen, Arena, Asana Biosciences, Aslan Pharmaceuticals, AstraZeneca, Boerhinger-Ingelhiem, Bristol-Meyers Squibb, Cara Therapeutics, Celgene, Connect Pharma, Eli Lilly, EMD Serono, Evidera, Galderma, Ichnos Sciences, Incyte, Janssen Biotech, Kyowa Kirin, Leo Pharma, Pandion Therapeutics, Pfizer, RAPT Therapeutics, Regeneron Pharmaceuticals, Inc, Sanofi, SATO Pharmaceutical, Siolta Therapeutics, Target Pharma Solutions, UCB, and Ventyx Biosciences. Funding: This study is funded by the Edelstein Family Chair of Pediatric Allergy-Immunology.

PY - 2022/4

Y1 - 2022/4

UR - http://www.scopus.com/inward/record.url?scp=85124978149&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85124978149&partnerID=8YFLogxK

U2 - 10.1016/j.anai.2022.01.023

DO - 10.1016/j.anai.2022.01.023

M3 - Editorial

C2 - 35093553

AN - SCOPUS:85124978149

SN - 1081-1206

VL - 128

SP - 344

EP - 345

JO - Annals of Allergy, Asthma and Immunology

JF - Annals of Allergy, Asthma and Immunology

IS - 4

ER -

New therapies for atopic dermatitis: How will they impact skin care?

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this